Literature DB >> 24337132

Health-related quality of life in epidermolysis bullosa: Validation of the Dutch QOLEB questionnaire and assessment in the Dutch population.

Wing Yan Yuen1, John W Frew, Kelly Veerman, Edwin R van den Heuvel, Dedee F Murrell, Marcel F Jonkman.   

Abstract

Defining the health-related quality of life (HRQoL) in patients suffering from the heritable blistering disease epidermolysis bullosa (EB) is important in assessing the efficacy of new treatments. The quality of life in EB questionnaire (QOLEB) is an English 17-item EB-specific HRQoL measurement tool. The aim of this study was to develop a validated and reliable QOLEB in Dutch and assess the HRQoL in Dutch EB patients. The QOLEB was translated to Dutch according to protocol. Fifty-five adult patients across 4 EB subtypes participated. The QOLEB had excellant correlation with the Skindex-29 (ρs = 0.86), good correlation with the SF-36 physical score (ρs = -0.75), and moderate correlation with the SF-36 mental score (ρs = -0.43). The discriminative validity between the 4 different EB subtypes was significant (p = 0.002). The internal consistency was excellent (α = 0.905), and the test-retest reliability strong (ρs = 0.88). In conclusion, the Dutch QOLEB is a reliable and valid instrument for the assessment of the HRQoL in adult EB patients.

Entities:  

Mesh:

Year:  2014        PMID: 24337132     DOI: 10.2340/00015555-1758

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  13 in total

Review 1.  Psychosocial impact of inherited and autoimmune blistering diseases.

Authors:  Swaranjali V Jain; Dedee F Murrell
Journal:  Int J Womens Dermatol       Date:  2018-01-08

2.  A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex.

Authors:  Jodi Y So; Shivali Fulchand; Christine Y Wong; Shufeng Li; Jaron Nazaroff; Emily S Gorell; Mark P de Souza; Dedee F Murrell; Joyce M Teng; Albert S Chiou; Jean Y Tang
Journal:  Orphanet J Rare Dis       Date:  2022-07-15       Impact factor: 4.303

3.  The quality of life in epidermolysis bullosa (EB-QoL) questionnaire: Translation, cultural adaptation, and validation into the Farsi language.

Authors:  Atoosa Yazdanshenas; Ezatollah Naderi; Hamideh Moravvej; Kazem Heidari; Masoomeh Faghankhani; Hassan Vahidnezhad; Nikoo Mozafari
Journal:  Int J Womens Dermatol       Date:  2020-06-03

4.  A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB).

Authors:  Clare L Rogers; Matthew Gibson; Johannes S Kern; Linda K Martin; Susan J Robertson; Benjamin S Daniel; John C Su; Oliver G C Murrell; Grant Feng; Dedee F Murrell
Journal:  JAAD Int       Date:  2021-01-21

5.  Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe.

Authors:  Aris Angelis; Panos Kanavos; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; Valentin Brodszky; Johann Matthias Graf von der Schulenburg; Karine Chevreul; Ulf Persson; Giovanni Fattore
Journal:  Eur J Health Econ       Date:  2016-04-23

Review 6.  Disease-specific health related quality of life patient reported outcome measures in Genodermatoses: a systematic review and critical evaluation.

Authors:  John W Frew; Mark Davidson; Dedee F Murrell
Journal:  Orphanet J Rare Dis       Date:  2017-12-29       Impact factor: 4.123

7.  Pain and quality of life evaluation in patients with localized epidermolysis bullosa simplex.

Authors:  Jennifer Brun; Christine Chiaverini; Caroline Devos; Stéphanie Leclerc-Mercier; Juliette Mazereeuw; Emmanuelle Bourrat; Annabel Maruani; Stéphanie Mallet; Claire Abasq; Alice Phan; Pierre Vabres; Ludovic Martin; Christine Bodemer; Sylvie Lagrange; Jean-Philippe Lacour
Journal:  Orphanet J Rare Dis       Date:  2017-06-28       Impact factor: 4.123

8.  The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa.

Authors:  S V Jain; A G Harris; J C Su; D Orchard; L J Warren; H McManus; D F Murrell
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-10-03       Impact factor: 6.166

9.  Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases.

Authors:  N H B Schräder; J C Duipmans; B Molenbuur; A P Wolff; M F Jonkman
Journal:  Br J Dermatol       Date:  2018-11-14       Impact factor: 9.302

10.  Identifying Epidermolysis Bullosa Patient Needs and Perceived Treatment Benefits: An Explorative Study Using the Patient Benefit Index.

Authors:  Nicholas H B Schräder; Eva W H Korte; José C Duipmans; Roy E Stewart; Maria C Bolling; André P Wolff
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.